Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of Asimadoline in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)

NCT01100684 is registered in ClinicalTrials.gov with Tioga Pharmaceuticals as lead sponsor.

NCT NCT01100684
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01100684 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of Asimadoline in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
Lead sponsor
Tioga Pharmaceuticals
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2010
Completion date
June 30, 2013
Enrollment
611 (actual)
Sites
142

Conditions

As the registry lists them; a condition with its own page is linked.

diarrhea predominant irritable bowel syndrome